Literature DB >> 10630188

ALS-linked Cu/Zn-SOD mutation increases vulnerability of motor neurons to excitotoxicity by a mechanism involving increased oxidative stress and perturbed calcium homeostasis.

I I Kruman1, W A Pedersen, J E Springer, M P Mattson.   

Abstract

We employed a mouse model of ALS, in which overexpression of a familial ALS-linked Cu/Zn-SOD mutation leads to progressive MN loss and a clinical phenotype remarkably similar to that of human ALS patients, to directly test the excitotoxicity hypothesis of ALS. Under basal culture conditions, MNs in mixed spinal cord cultures from the Cu/Zn-SOD mutant mice exhibited enhanced oxyradical production, lipid peroxidation, increased intracellular calcium levels, decreased intramitochondrial calcium levels, and mitochondrial dysfunction. MNs from the Cu/Zn-SOD mutant mice exhibited greatly increased vulnerability to glutamate toxicity mediated by alpha-amino-3-hydroxy-5-methylisoxazole-4-propionate receptors. The increased vulnerability of MNs from Cu/Zn-SOD mutant mice to glutamate toxicity was associated with enhanced oxyradical production, sustained elevations of intracellular calcium levels, and mitochondrial dysfunction. Pretreatment of cultures with vitamin E, nitric oxide-suppressing agents, peroxynitrite scavengers, and estrogen protected MNs from Cu/Zn-SOD mutant mice against excitotoxicity. Excitotoxin-induced degeneration of spinal cord MNs in adult mice was more extensive in Cu/Zn-SOD mutant mice than in wild-type mice. The mitochondrial dysfunction associated with Cu/Zn-SOD mutations may play an important role in disturbing calcium homeostasis and increasing oxyradical production, thereby increasing the vulnerability of MNs to excitotoxicity.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10630188     DOI: 10.1006/exnr.1999.7190

Source DB:  PubMed          Journal:  Exp Neurol        ISSN: 0014-4886            Impact factor:   5.330


  59 in total

1.  Caspase-mediated degradation of AMPA receptor subunits: a mechanism for preventing excitotoxic necrosis and ensuring apoptosis.

Authors:  G W Glazner; S L Chan; C Lu; M P Mattson
Journal:  J Neurosci       Date:  2000-05-15       Impact factor: 6.167

Review 2.  Mitochondrial dysfunction in familial amyotrophic lateral sclerosis.

Authors:  Liesbeth Faes; Geert Callewaert
Journal:  J Bioenerg Biomembr       Date:  2011-12       Impact factor: 2.945

Review 3.  Excitotoxic and excitoprotective mechanisms: abundant targets for the prevention and treatment of neurodegenerative disorders.

Authors:  Mark P Mattson
Journal:  Neuromolecular Med       Date:  2003       Impact factor: 3.843

Review 4.  Human stem cells and drug screening: opportunities and challenges.

Authors:  Allison D Ebert; Clive N Svendsen
Journal:  Nat Rev Drug Discov       Date:  2010-03-26       Impact factor: 84.694

5.  Neuroprotective and neurorestorative strategies for neuronal injury.

Authors:  M F Beal; T Palomo; R M Kostrzewa; T Archer
Journal:  Neurotox Res       Date:  2000       Impact factor: 3.911

Review 6.  Mitochondrial dysfunction in amyotrophic lateral sclerosis.

Authors:  Ping Shi; Jozsef Gal; David M Kwinter; Xiaoyan Liu; Haining Zhu
Journal:  Biochim Biophys Acta       Date:  2009-08-26

Review 7.  Endoplasmic reticulum Ca(2+) handling in excitable cells in health and disease.

Authors:  Grace E Stutzmann; Mark P Mattson
Journal:  Pharmacol Rev       Date:  2011-07-07       Impact factor: 25.468

Review 8.  Glutamate and neurotrophic factors in neuronal plasticity and disease.

Authors:  Mark P Mattson
Journal:  Ann N Y Acad Sci       Date:  2008-11       Impact factor: 5.691

9.  Impact of mitochondrial inhibition on excitability and cytosolic Ca2+ levels in brainstem motoneurones from mouse.

Authors:  Friederike Bergmann; Bernhard U Keller
Journal:  J Physiol       Date:  2003-12-05       Impact factor: 5.182

10.  Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases.

Authors:  Douglas B Kell
Journal:  BMC Med Genomics       Date:  2009-01-08       Impact factor: 3.063

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.